Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$127.59 USD

127.59
735,526

-0.22 (-0.17%)

Updated Aug 7, 2025 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Best Value Stocks to Buy for August 30th

by Zacks Equity Research

RCMT, AIZ and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 30, 2024.

Zacks Equity Research

COO Stock Gains on Q3 Earnings & Revenue Beat, Margins Up

by Zacks Equity Research

Cooper Companies' solid segmental results led to an encouraging fiscal third-quarter performance, driving up share prices in after-hours trading.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

The Zacks Analyst Blog Highlights DaVita and Illumina

by Zacks Equity Research

DaVita and Illumina are included in this Analyst Blog.

Zacks Equity Research

Zacks Investment Ideas feature highlights: DaVita, Starwood Property and Philip Morris

by Zacks Equity Research

DaVita, Starwood Property and Philip Morris have been highlighted in this Investment Ideas article.

Ethan Feller headshot

3 Defensive Stocks Outperforming in a Choppy Market (PM, DVA, STWD)

by Ethan Feller

Philip Morris International, Starwood Property Trust and DaVita all show relative strength and top Zacks Ranks

Zacks Equity Research

PDCO Stock Falls on Q1 Earnings & Sales Miss, Gross Margin Up Y/Y

by Zacks Equity Research

Patterson Companies' first-quarter fiscal 2025 results reflect the negative impact of a cyberattack on its vendor, Change Healthcare.

Indrajit Bandyopadhyay headshot

Aveanna Stock Rallies 110% in 3 Months: Is It Still Worth Buying?

by Indrajit Bandyopadhyay

AVAH stock has the potential to continue its uptrend on the back of a better payer rate environment and its focus on high-paying customers.

Nalak Das headshot

2 Must-Buy Medical Stocks With Strong Momentum

by Nalak Das

Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.

Zacks Equity Research

Reasons to Retain Stryker Stock in Your Portfolio for Now

by Zacks Equity Research

SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Zacks Equity Research

Reasons to Retain Fresenius Medical Stock in Your Portfolio Now

by Zacks Equity Research

FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.

Zacks Equity Research

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition

by Zacks Equity Research

McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.

Zacks Equity Research

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Zacks Equity Research

Best Momentum Stock to Buy for August 27th

by Zacks Equity Research

DVA, MRX and AIZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 27, 2024.

Zacks Equity Research

Is DaVita (DVA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Zacks Equity Research

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

Zacks Equity Research

Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.

Zacks Equity Research

Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y

by Zacks Equity Research

Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.

Zacks Equity Research

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Zacks Equity Research

Why You Should Add HCA Healthcare (HCA) to Your Portfolio Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on growing emergency room visits, buyouts and solid cash flows.